Testing a heart-protective medication for breast cancer patients

Plain-English translation of NCT07233499 on ClinicalTrials.gov ↗ · Source last updated November 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether a medication called nebivolol can protect your heart while you receive trastuzumab, a standard breast cancer treatment. Trastuzumab is very effective at treating HER2-positive breast cancer, but it can sometimes damage the heart as a side effect. This study will see if taking the medication daily can prevent that heart damage.

Trastuzumab has saved many lives by treating HER2-positive breast cancer, but doctors have noticed it can weaken the heart in some patients. This medication is being tested to find out if it can protect your heart during cancer treatment, so you get the benefits of trastuzumab without the heart-related risks.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been newly diagnosed with early or locally advanced HER2-positive breast cancer
your heart function is normal before starting the trial
you are planned to receive trastuzumab as part of your breast cancer treatment

You likely don't qualify if…

you are over 65 years old
you are currently taking other heart-protective medications or beta-blockers
you have a diagnosed heart condition or cardiomyopathy
you have a history of heart disease or poor blood flow to the heart
you are pregnant or breastfeeding

What participation looks like

If you join this study, you would be randomly assigned to either take the heart-protective medication once daily by mouth during your entire trastuzumab treatment, or to receive no additional medication. Throughout your cancer treatment, you would continue your regular cancer care visits and heart monitoring. The researchers will check your heart function regularly to see if the medication helps prevent damage.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(1 site)

Egypt

National Cancer Institute- Cairo University- Egypt, Cairo

Key details

Phase

Testing effectiveness

Sponsor

Ain Shams University

Collaborators

National Cancer Institute, Egypt

Enrollment target

~56 participants

Started

January 2025

Primary completion

February 2027

Age range

18 Years – 65 Years

Sex

Female only

Last updated on clinicaltrials.gov in November 2025.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

May A Shawki, Ph.D

Ain Shams University

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

View full record on ClinicalTrials.gov